The terms PSUR, DSUR, and PBRER are used interchangeably in conversation — but they are three structurally distinct documents with different ICH guidelines, different submission triggers, and different reporting requirements. Misunderstanding the difference at scoping leads to scope creep, deadline pressure, and avoidable audit findings.
The three reports — what each one is
PSUR — Periodic Safety Update Report
A PSUR is the periodic safety report for marketed pharmaceutical products. It is submitted to regulators under ICH E2C(R2) structure and integrates the full picture of a product's safety over a defined data lock point (DLP) interval.
What it covers: worldwide marketing authorisation status, regulatory actions taken for safety reasons, changes to reference safety information, patient exposure, literature, ongoing studies, signal evaluation, and an overall benefit-risk evaluation.
DSUR — Development Safety Update Report
A DSUR is the annual safety report for products in clinical development — i.e., investigational medicinal products (IMPs) under active IND, CTN, or equivalent. Submitted under ICH E2F.
What it covers: clinical trial safety data integration, IND annual reports, Development Core Safety Information (DCSI) maintenance, IMP exposure estimation, SUSAR line listings, and ongoing/completed trial summaries.
PBRER — Periodic Benefit-Risk Evaluation Report
A PBRER is the EMA-mandated format for periodic safety reporting under ICH E2C(R2). Structurally, it follows the PSUR template — with explicit benefit characterisation, risk characterisation, and integrated benefit-risk analysis sections that EMA requires.
If you submit to EMA, you write a PBRER. If you submit to other markets following ICH E2C(R2), the document is structurally the same but typically referred to as a PSUR.
Quick comparison
| Dimension | PSUR | DSUR | PBRER |
|---|---|---|---|
| ICH guideline | E2C(R2) | E2F | E2C(R2) |
| Applies to | Marketed products | Investigational products | Marketed products (EMA) |
| Submission trigger | DLP-based (typically 6m / yearly / 3-yearly) | Annual (development period anniversary) | DLP-based (EMA EURD list) |
| Benefit-risk section | Yes — overall evaluation | Implicit | Yes — explicit characterisation |
| Reference document | CCSI or approved SmPC | Development CSI | CCSI or approved SmPC |
CDSCO requirements for Indian marketing authorisations
CDSCO has adopted ICH E2C(R2) for periodic safety reporting requirements for products with Indian marketing authorisations. The reporting frequency follows the standard ICH cycle (6-monthly for first two years post-approval, then yearly, then 3-yearly).
For multi-market products, the standard practice is to maintain a core PSUR built to ICH E2C(R2) and produce market-specific addenda that address CDSCO-specific patient exposure (sales volumes for India) and any India-specific safety actions taken since the previous DLP.
The 5 most common errors in PSUR writing
- Literature search not reproducible — search strings constructed from memory, undocumented de-duplication, missing audit logs. The #1 audit finding in CDSCO and EMA inspections.
- Patient exposure section misaligned with safety data DLP — sales volumes covering a different period than the safety database query. Inspectors check this consistency every time.
- Signal evaluation conclusions without supporting evidence — a signal labelled "not confirmed" without documentation of what was evaluated. The remediation cycle is brutal.
- Reference safety information out of date — the CCSI or approved SmPC used in the PSUR not matching the current approved version. Triggers regulatory queries.
- Benefit-risk section drafted last — written after the rest of the report, often inconsistent with the safety evaluation it should reflect. Sign of process rather than scientific failure.
What good PSUR writing looks like (in 2026)
In 2026, the standard for PSUR writing has shifted in three ways:
- Literature search is auditable by construction — every search string, every de-duplication decision, every evidence quality score documented. Tools like Pharos Scout produce the audit trail automatically.
- Signal evaluation is documented as a structured decision — not a narrative. Each signal evaluated against a defined framework with documented inputs, deliberation, and conclusion.
- 4-layer sequential QC replaces the "two reviewer" model — Scientific → Editorial → Compliance → Technical. Each layer signs off before the next begins.
Need a PSUR, DSUR, or PBRER written?
ICG writes all three formats — ICH E2C(R2) and ICH E2F compliant, audit-ready by design, with 4-layer sequential QC on every deliverable. Start with a pilot section in 48 hours.
What is a PSUR?
A Periodic Safety Update Report (PSUR) is submitted for marketed pharmaceutical products under ICH E2C(R2). It integrates worldwide marketing authorisation status, patient exposure, literature, ongoing studies, signal evaluation, and benefit-risk assessment over a defined data lock point interval.
What is a DSUR?
A Development Safety Update Report (DSUR) covers investigational medicinal products under ICH E2F — an annual report on the safety of drugs in clinical development.
What is a PBRER?
A Periodic Benefit-Risk Evaluation Report (PBRER) is the EMA's implementation of ICH E2C(R2) — structurally similar to a PSUR but with explicit benefit-risk integration sections required by EMA.
Does CDSCO require PSURs for Indian marketing authorisations?
Yes. CDSCO requires periodic safety reports for marketed products in India, adopted from ICH E2C(R2) structure.
What is the most common PSUR writing error?
A literature search methodology that cannot be reproduced at inspection. Search strings constructed from memory, undocumented de-duplication, and missing audit logs are routinely flagged in PV audits.
